To the full analysis
Glenmark Pharmaceuticals stock: growth
GLENMARK.NSGlenmark Pharmaceuticals reported $1.81B in revenue for fiscal 2026, up 27.1% on the prior year, up 9.2% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
14.7%
per year from 2007 to 2026, per share 13.7%
Earnings (Annual rate)
8.1%
per year from 2007 to 2026, per share 7.2%
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2021 | since 2016 | since 2007 | |
|---|---|---|---|
| Revenue | 9.2% | 8.4% | 14.7% |
| Revenue per share | 9.2% | 8.4% | 13.7% |
| Earnings | 7.0% | 6.8% | 8.1% |
| Earnings per share | 7.0% | 6.8% | 7.2% |
| Free cash flow | 40.4% | no data | no data |
| Free cash flow per share | 40.4% | no data | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2007 | $133.02M | $32.96M | −$19.82M |
| 2008 | $213.55M | $67.19M | −$16.05M |
| 2009 | $224.91M | $20.56M | −$101.88M |
| 2010 | $265.79M | $35.18M | −$4.61M |
| 2011 | $313.45M | $48.66M | $56.24M |
| 2012 | $427.35M | $48.93M | $55.16M |
| 2013 | $528.85M | $65.9M | $18.81M |
| 2014 | $631.88M | $57.64M | $50.71M |
| 2015 | $696.84M | $50.52M | −$6.65M |
| 2016 | $804.95M | $74.62M | −$57.97M |
| 2017 | $965.04M | $97.36M | −$9.68M |
| 2018 | $964.51M | $85.44M | $64.14M |
| 2019 | $1.05B | $98.32M | $9.25M |
| 2020 | $1.13B | $82.48M | $49M |
| 2021 | $1.16B | $103.1M | $37.89M |
| 2022 | $1.31B | $100.09M | $33.86M |
| 2023 | $1.24B | $31.59M | $1.87M |
| 2024 | $1.34B | −$159.61M | −$123.7M |
| 2025 | $1.42B | $111.29M | −$167.63M |
| 2026 | $1.81B | $144.75M | $206.35M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2026, period end 31 Mar 2026
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = ₹94.0836)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 31 Jul 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.